Aquestive Therapeutics (AQST) Equity Ratio (2017 - 2026)

Aquestive Therapeutics' Equity Ratio history runs 10 years deep, the most recent figure standing at 0.24 for Q1 2026.

• In Q1 2026, Equity Ratio rose 59.51% year-over-year to 0.24; the TTM figure through Mar 2026 stood at 0.24 (up 59.51% YoY), while the FY2025 annual figure was 0.21, up 64.62% from the prior year.
• Equity Ratio was 0.24 for Q1 2026 at Aquestive Therapeutics, down from 0.21 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.03 in Q3 2025 to a low of 2.08 in Q3 2022.
• Historically, Equity Ratio has averaged 1.07 across 5 years, with a median of 0.77 in 2025.
• Biggest YoY gain for Equity Ratio was 93.92% in 2025; the steepest drop was 156.8% in 2025.
• A 5-year view of Equity Ratio shows it stood at 2.08 in 2022, then gained by 10.72% to 1.85 in 2023, then jumped by 68.02% to 0.59 in 2024, then soared by 64.62% to 0.21 in 2025, then retreated by 15.0% to 0.24 in 2026.
• The last three Equity Ratio figures came in at 0.24 (Q1 2026), 0.21 (Q4 2025), and 0.03 (Q3 2025), per Business Quant data.